Purchase Order 36C25026P0405
- Not listed
- Cepheid Inc., headquartered in Sunnyvale, California, was awarded a delivery order valued at $202,883.65 by the Veterans Integrated Service Network (VISN) 6 on April 1, 2025, for Cepheid molecular diagnostic testing system reagents, assays, and lease services. This firm fixed-price delivery order, with an ultimate completion date of September 30, 2025, operates under a larger single-award Indefinite Delivery Contract (IDC) between Cepheid and VISN 6 valued at $32.8 million and extending...
- Cepheid Inc. has been awarded a delivery order valued at $247,262.22 by Veterans Integrated Service Network 9 (VISN 9), a component of the Department of Veterans Affairs, for Cepheid medical equipment reagents to support patient testing. This firm fixed-price delivery order, with an ultimate completion date of September 30, 2026, carries no set-aside designation and represents a continuation of the company's established role as a primary supplier of molecular diagnostic solutions to the VA...
- Cepheid has been awarded a firm fixed-price delivery order valued at $40,704.72 by the Department of Veterans Affairs' Veterans Integrated Service Network 9 (VISN 9). The contract, with an ultimate completion date of May 31, 2025, is for molecular diagnostic solutions to be delivered and performed in Sunnyvale, California. This delivery order carries no set-aside designation and represents a continuation of Cepheid's ongoing provision of advanced diagnostic systems and testing solutions to the...
- Cepheid Inc. was awarded a $306,000 firm fixed-price delivery order by the Department of Veterans Affairs' Veterans Integrated Service Network 21 (VISN 21) on October 1, 2025, for the supply of Cepheid testing kits. The contract carries an ultimate completion date of March 31, 2026, with no set-aside designation. As a molecular diagnostics manufacturer headquartered in Sunnyvale, California, Cepheid supplies the federal healthcare system with advanced diagnostic solutions, particularly its...
- Cepheid Inc. has been awarded a delivery order valued at $333,567.56 by the Department of Veterans Affairs' Veterans Integrated Service Network 21 (VISN 21), with a firm fixed-price structure and ultimate completion date of March 15, 2026. This delivery order represents a continuation of the agency's procurement of molecular diagnostic solutions from Cepheid, a Sunnyvale, California-based manufacturer specializing in advanced diagnostic systems and reagents. The award carries no set-aside...
- Cepheid has been awarded a delivery order valued at $132,650.80 under its larger Indefinite Delivery Contract (IDC) with the Department of Veterans Affairs Veterans Integrated Service Network 6 (VISN 6). This delivery order, issued on January 9, 2025, with a completion date of March 31, 2025, is for Cepheid molecular diagnostic testing system reagents, assays, and equipment lease to support VISN 6 medical center laboratories. The contract utilizes firm fixed-price pricing with no set-aside...
- Cepheid Inc., headquartered in Sunnyvale, California, was awarded a $2.27 million firm fixed-price purchase order by the Department of Veterans Affairs through Veterans Integrated Service Network 20 for the lease and purchase of a molecular diagnostic testing system along with instrument-specific assays. The contract, awarded on August 1, 2022, with an ultimate completion date of July 31, 2027, carries no set-aside designation and represents part of the VA's broader reliance on Cepheid as a...
- Cepheid Inc., headquartered in Sunnyvale, California, was awarded a delivery order valued at $229,673.34 by Veterans Integrated Service Network 6 (VISN 6) on April 1, 2025, for Cepheid molecular diagnostic testing system reagents, assays, and equipment lease. The order is structured as a firm fixed-price delivery order with no set-aside designation and is scheduled for completion by September 30, 2025. This delivery order is issued under Cepheid's larger Indefinite Delivery Contract with VISN 6,...
- Cepheid was awarded a delivery order valued at $172,259.87 for Cepheid reagents by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 16 on October 1, 2024. This firm fixed-price contract, with an ultimate completion date of September 30, 2025, carries no set-aside designation. The work will be performed in Sunnyvale, California. Cepheid is a leading manufacturer of molecular diagnostic solutions specializing in advanced diagnostic systems and test kits for infectious...
- Cepheid Inc., a manufacturer of molecular diagnostic solutions based in Sunnyvale, California, was awarded a purchase order valued at $5.17 million by the Department of Veterans Affairs' Veterans Integrated Service Network 8 on October 1, 2022. This firm fixed-price contract, with no set-aside designation, is a modification to an existing agreement that adjusts clinical quantities based on updated workload estimates for microbiology testing services. The contract calls for an all-inclusive...
Cepheid Inc., headquartered in Sunnyvale, California, has been awarded a $613,093.80 firm fixed-price purchase order by the Department of Veterans Affairs' Veterans Integrated Service Network 22 (VISN 22) for Cepheid reagents. The contract was awarded on March 1, 2026, with an ultimate completion date of February 28, 2027, and carries no set-aside designation. As a leading supplier of molecular diagnostic solutions to the federal healthcare system, Cepheid will deliver diagnostic reagents and test kits designed for the company's GeneXpert diagnostic platform, which is widely deployed across VA medical centers for infectious disease testing and clinical diagnostics. This purchase order award reflects Cepheid's established role as a core supplier to the VA system, supported by the company's broader portfolio of Indefinite Delivery Contracts with multiple VA networks, including a $32.8 million IDC with VISN 6 extending through 2030. Cepheid's diagnostic capabilities span testing for COVID-19, influenza, respiratory syncytial virus, tuberculosis, sexually transmitted infections, and antimicrobial-resistant pathogens, making the company an essential partner in supporting VA laboratory operations and clinical care delivery across the distributed network of VA medical facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $613.1k | 2/26/26 |